12/16/2020 8:32:44 AM
DURECT Says FDA Granted Fast Track Designation To DUR-928 For Treatment Of Alcoholic Hepatitis
11/13/2020 9:08:42 AM
DURECT Announces Addl Safety Data And Efficacy Signals From Phase 1b Clinical Trial Of DUR-928 In NASH Patients
9/23/2020 8:36:00 AM
DURECT: First Patient Dosed In Phase 2 Study Of DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury
9/22/2020 8:34:41 AM
DURECT Announces Study Design For Phase 2b AHFIRM Clinical Trial Of DUR-928 In Severe AH Patients
8/27/2020 8:36:15 AM
DURECT Announces Presentation Of Phase 2a Pharmacokinetic Data Of DUR-928 In Alcoholic Hepatitis
7/1/2020 8:46:52 AM
DURECT Begins Recruiting Patients For Phase 2 Study On DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury
5/26/2020 8:33:17 AM
DURECT Announces Positive Topline Data From Phase 1b Study Of DUR-928 In NASH
1/17/2020 6:50:38 AM
DURECT Says FDA Committee Voted 6-6 On Safety And Efficacy Of POSIMIR
1/16/2020 7:08:02 AM
DURECT Trading Halted Today; FDA Advisory Committee To Discuss POSIMIR For Post-Surgical Analgesia
1/2/2020 9:02:52 AM
DURECT Reports Results From Phase 2a Clinical Trial Of DUR-928 In Patients With Mild To Moderate Plaque Psoriasis
11/12/2019 8:50:47 AM
DURECT Announces Positive Results From Phase 2a Trial Of DUR-928 In Alcoholic Hepatitis Patients
10/7/2019 8:03:53 AM
DURECT Closes Enrollment In Phase2a Trial Of DUR-928 In Psoriasis And 50% Enrollment In Phase 1b DUR-928 Trial In NASH
10/2/2019 8:05:59 AM
DURECT Reports FDA Advisory Committee Meeting To Review POSIMIR For Treatment Of Post-Surgical Pain